Palantir Technologies raises its full-year outlook but the stock falls, while Ford suspends guidance because of uncertainty ...

Hims & Hers Health first-quarter revenue more than doubled as subscribers rose 38%, while its second-quarter sales outlook ...

That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...

Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

Hims & Hers Health (NYSE:HIMS) stock spikes, risking a short squeeze given its elevated short interest. Read more here.

Shares of Hims & Hers Health ( HIMS -5.48%) and LifeMD ( LFMD -14.33%) are surging on Tuesday. The companie' stocks had ...

Novo Nordisk said it would sell its popular weight-loss drug Wegovy on several telehealth platforms, including Hims.

Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...

Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with ...